Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP

Table 4 Dynamic changes of variables between baseline and after 3 cycles of (R)-CHOP in DLBCL patients

Variable	At baseline	After 3 cycles of (R)-CHOP	P-value	d (after—baseline)^a
HDL-C
No-AISC	1.07 (0.81, 1.38)	1.27 (0.96, 1.49)	0.010	0.18 (-0.14, 0.27)
AISC	0.97 (0.86, 1.20)	1.08 (0.81, 1.61)	0.219	0.09 (-0.16, 0.28)
P-value	0.410	0.062		0.005
ApoA1
No-AISC	1.18 ± 0.36	1.34 ± 0.2	0.038	1.22 ± 0.33
AISC	1.17 ± 0.29	1.24 ± 0.30	0.145	1.10 ± 0.30
P-value	0.913	0.162		0.795
e’
No-AISC	6.92 ± 1.98	7.04 ± 2.42	0.599	0.14 ± 1.65
AISC	7.85 ± 2.02	6.52 ± 2.08	0.001	-1.33 ± 0.34
P-value	0.067	0.365		0.001
TG
No-AISC	1.25 (0.91, 1.55)	1.38 (0.98, 2.00)	0.004	0.22 (-0.08, 0.69)
AISC	1.54 (1.27, 1.92)	2.01 (1.53, 3.15)	0.081	0.28 (-0.23, 1.23)
P-value	0.009	0.003		0.814

Values are expressed as mean ± standard deviation or median (Q1-Q3). Bold values indicate statistical significance
^a Difference value of variables measured after 3 cycles of (R)-CHOP and at baseline
AISC Anthracycline-induced subclinical cardiotoxicity, ApoA1 Apolipoprotein A1, DLBCL Diffuse large-B cell lymphoma, HDL-C High-density lipoprotein cholesterol, TG Total triglyceride

ISSN: 1471-2407